These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34265398)

  • 1. Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance.
    Wang LT; Liu KY; Chiou SS; Huang SK; Hsu SH; Wang SN
    Cancer Lett; 2021 Nov; 520():160-171. PubMed ID: 34265398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestine-specific homeobox (ISX) upregulates E2F1 expression and related oncogenic activities in HCC.
    Wang SN; Wang LT; Sun DP; Chai CY; Hsi E; Kuo HT; Yokoyama KK; Hsu SH
    Oncotarget; 2016 Jun; 7(24):36924-36939. PubMed ID: 27175585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proinflammatory homeobox gene, ISX, regulates tumor growth and survival in hepatocellular carcinoma.
    Hsu SH; Wang LT; Lee KT; Chen YL; Liu KY; Suen JL; Chai CY; Wang SN
    Cancer Res; 2013 Jan; 73(2):508-18. PubMed ID: 23221382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity.
    Chuang KT; Wang SN; Hsu SH; Wang LT
    Cancer Med; 2021 Aug; 10(16):5545-5556. PubMed ID: 34173348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.
    Mehdizadeh A; Somi MH; Darabi M; Jabbarpour-Bonyadi M
    Mol Biol Rep; 2016 Feb; 43(2):107-16. PubMed ID: 26767647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl hydrocarbon receptor promotes hepatocellular carcinoma tumorigenesis by targeting intestine-specific homeobox expression.
    Hsu SH; Wang LT; Chai CY; Wu CC; Hsi E; Chiou SS; Wang SN
    Mol Carcinog; 2017 Oct; 56(10):2167-2177. PubMed ID: 28398627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Liao LZ; Chen CT; Li NC; Lin LC; Huang BS; Chang YH; Chow LP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
    Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.
    Lin X; Li AM; Li YH; Luo RC; Zou YJ; Liu YY; Liu C; Xie YY; Zuo S; Liu Z; Liu Z; Fang WY
    Signal Transduct Target Ther; 2020 Feb; 5(1):13. PubMed ID: 32296025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
    Yan F; Wang XM; Pan C; Ma QM
    World J Gastroenterol; 2009 Mar; 15(12):1443-51. PubMed ID: 19322916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
    Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
    Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
    Ma Q; Xu Q; Zhao J; Zhang W; Wang Q; Fang J; Lu Z; Liu J; Ma L
    Cancer Lett; 2021 Nov; 520():243-254. PubMed ID: 34339801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
    Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
    Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
    Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
    Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.